A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...

Sun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes ...

A steady supply of weight-loss drugs Wegovy and Mounjaro has helped lift Eucalyptus’ revenue from $78 million to $121 million ...

Though the Healthy Skepticism ads don’t specifically call out compounded GLP-1s, Lilly said in a statement to MM+M that ...

On Monday, the company reported a 3.2% increase in first-half net income to R2.39bn. Aspen Pharmacare’s profit climbed after ...

China, India and the US will have the world’s largest populations of adults living with overweight and obesity by 2050, ...